Accelerating Heart Disease Research: Allen Institute’s New Disease-Specific Cell Lines
On June 4, 2024, the Allen Institute for Cell Science announced the launch of its first disease-specific cell line collections, marking a significant milestone in genetic heart disease research. This innovative set of tools, specifically designed to advance the study of hypertrophic cardiomyopathy (HCM) and other muscle disorders, represents a groundbreaking step in the quest […]
Pioneering Medical Breakthrough: Mouse Lungs Successfully Grown in Rats
In a world-first, researchers at the Phoenix Children’s Research Institute, part of the University of Arizona College of Medicine — Phoenix, have achieved a significant medical milestone that could pave the way for groundbreaking treatments of lung diseases. This innovative research marks a crucial step toward the potential of creating human lungs using large animals […]
CRISPR Therapeutics’ FDA Approval for CASGEVY™
CRISPR Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving CASGEVY™ (exagamglogene autotemcel [exa-cel]), a groundbreaking CRISPR/Cas9 gene-edited cell therapy. This approval makes CASGEVY available for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older. Approximately 1,000 patients in the U.S. are now eligible for […]
RoslinCT and the Revolutionary CRISPR-Based Gene Therapy CASGEVY™
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has achieved a groundbreaking milestone in the field of medical science. Building on its legacy since the cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has now been entrusted with the manufacturing of the first-ever U.S. Food and […]
RoslinCT Unveils CRISPR: A Medical Revolution Begins
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant advancement in the field of medical science. They will be manufacturing the world’s first CRISPR-based therapy, exa-cel, for Vertex Pharmaceuticals Inc. This development follows an extensive collaboration between the two entities. Key Highlights: About RoslinCT: RoslinCT has a […]
RoslinCT and Lykan Bioscience: The Dynamic Duo Redefining the Future of Cell and Gene Therapy
RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand. This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell […]
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the first patient has been enrolled in the company’s BEACON trial. BEACON is an open-label, single-arm, multicenter, Phase 1/2 clinical trial designed to evaluate the safety and efficacy of BEAM-101 in […]
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD33 and CLL-1 in human hematopoietic stem cells (HSCs) demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia (AML). The data […]
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies
NEW YORK, June 9, 2022 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced data demonstrating a statistically significant (p<0.01) 19% downregulation of mRNA and a ~40% reduction of alpha synuclein (α-synuclein) in an in vitro study […]
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present data later today on its SLEEK (SeLection by Essential- gene Exon Knock-in) gene editing technology during the New Gene Editing Technologies and Applications Session at the 25th Annual Meeting of the American Society of Gene and […]